Clinical dermatology company Sienna Biopharmaceuticals closes second Series A financing

July 19, 2016

Dermatology and aesthetics technology company Sienna Biopharmaceuticals has completed a second closing of its Series A financing.

BioOptics World Editors

Sienna Biopharmaceuticals (Westlake Village, CA), a clinical stage company that focuses on dermatology and aesthetics, has completed a second closing of its Series A financing, securing an additional $12 million in equity capital and bringing the total capital raised to approximately $46 million.

The company is developing novel approaches to treat skin based on plasmonic resonance, originally developed at Sienna Labs (Carlsbad, CA) under the leadership of Todd Harris, Ph.D. The technology, called Silver Plasmonic Therapy (SPT), entails using a proprietary topical solution containing patented plasmonic particles that interact with the light emitted by existing medical laser systems, allowing controlled targeting of microstructures in the skin. The company believes the treatment has the potential to meet unmet needs in the areas of acne, hair removal, and potentially other areas.

The additional investment proceeds are targeted to fund the company's pharmaceutical research and advance its business development efforts. Clinical trials are already underway and the company is evaluating additional potential indications.

For more information, please visit www.siennabio.com.

About the Author

BioOptics World Editors

We edited the content of this article, which was contributed by outside sources, to fit our style and substance requirements. (Editor’s Note: BioOptics World has folded as a brand and is now part of Laser Focus World, effective in 2022.)